Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO)
PR Newswire · 23 Oct 2026
Intensity Therapeutics (INTS) Slips 2.12% to $3.35 as Shares Drift Toward Lower Range - Revenue Weighted
https://www.siam.in/ · 17 Oct 2026
Intensity Therapeutics (INTS) Stock Analysis Report | Financials & Insights
Benzinga España · 27 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.